Cancer Survival Rates Hit 70% Milestone, but Progress Faces New Threat
Table of Contents
A landmark report reveals that for the first time, 70% of individuals diagnosed with cancer in the United States between 2015 and 2021 are surviving at least five years. Though, this hard-won progress is now jeopardized by potential federal cuts to crucial research funding and healthcare access.
Approximately 2,114,850 new cancer cases are expected to be diagnosed this year, with 626,140 resulting in death, underscoring the continued burden of the disease. Despite remaining the second-leading cause of death overall and the primary cause of death for those under 85, the latest data from the American Cancer Society’s (ACS) Cancer Statistics, 2026 report demonstrates a significant and sustained decline in cancer mortality.
Decades of Progress yield Remarkable Results
Researchers analyzed data from central cancer registries and the National center for Health Statistics, revealing a 25% decline in overall cancer mortality rates as 1991. This translates to approximately 3.8 million fewer cancer deaths during that period. The decline is attributed to advancements in early detection, treatment, and prevention, with a 5-year relative survival rate of 70%, respectively.
The most significant gains have been observed among individuals diagnosed with historically high-mortality cancers and those with advanced diagnoses. These include:
- Multiple myeloma: Increased from 32% to 62% survival.
- Liver cancer: Improved from 7% to 22% survival.
- Metastatic melanoma: Rose from 16% to 35% survival.
- Metastatic rectal cancer: Increased from 8% to 18% survival.
- Regional lung cancer: Improved from 20% to 37% survival.
- Metastatic lung cancer: Increased from 2% to 10% survival.
Despite these encouraging advancements, lung cancer remains the deadliest form of the disease, projected to cause approximately 125,000 deaths in 2026 – exceeding the combined toll of colorectal and pancreatic cancers.
Disparities and Emerging Trends
The report also highlights critical disparities in cancer outcomes.Native American individuals experience the highest cancer mortality rates, with death rates roughly double those of White individuals for cancers of the kidney, liver, stomach, and uterus. They also exhibit the highest mortality rates from lung cancer, followed by White and Black individuals.
While the overall cancer mortality rate continues to decline,the incidence of many common cancers is increasing,including breast,prostate,liver (in females),melanoma (in females),oral cavity,pancreatic,and uterine corpus cancers. .
Cancer remains a significant health concern for young people, ranking as the second most common cause of death among children aged 1 to 14 (after accidents) and the fourth most common cause of death among adolescents aged 15 to 19. leukemia is the most prevalent childhood cancer, accounting for 28% of cases, closely followed by central nervous system tumors (27%), with a third of those tumors being benign or borderline malignant.
Funding Cuts Threaten Future Breakthroughs
The positive trajectory of cancer survival is now under threat,according to researchers,due to proposed federal cuts to both cancer research and health insurance programs.
“Although decades of scientific investment have translated into longer lives for most individuals diagnosed with cancer, pending federal cuts to health insurance and cancer research will inevitably reduce access to life-saving drugs and halt progress at a time when incidence is rising for many common cancers,” a senior official stated.
Shane Jacobson, Chief Executive Officer of the ACS and the ACS Cancer Action Network, echoed these concerns, emphasizing the federal government’s ancient role as the largest funder of cancer research. “For decades, the federal government has been the largest funder of cancer research, which has translated to longer lives for people with even the most fatal cancers.But now,threats to cancer research funding and significant impact to access to health insurance could reverse this progress and stall future breakthroughs. We can’t stop now. There is still much work to be done.”
The future of cancer research and patient care hangs in the balance, demanding continued investment and unwavering commitment to ensure further progress against this devastating disease.
